Nurses Can Help Mitigate Prostate Cancer Disparities

Video

Disparities exist across many cancer types, but they are particularly prevalent in patients with prostate cancer, explained Maggie A. Smith, DNP, MSN/Ed, RN, OCN, field medical director in GU Oncology at Pfizer, and Oncology Nursing News contributor.

African American men have some of the highest incidences and mortality rates from prostate cancer. To address this, oncology nurses can push for more inclusion in clinical trials, and educate their African American patients on the disease and prevention.

Recent Videos
5 experts in this video
5 experts in this video
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
5 experts in this video
5 experts in this video
Related Content
Blue image of kidneys with renal tubules highlighted in red

Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

Tim Cortese
February 15th 2025
Article

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

The Vitals

Linda Bloom Shares Strategies To Improve Presurgical Communication With Patients Who Have Limited English Proficiency

Lindsay Fischer
August 14th 2023
Podcast

Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.

Graphic of care providers, patients, and families conversing near large computers and health charts

Digital Health Tool Helps Patients With Prostate Cancer During Consultations

Bridget Hoyt
February 14th 2025
Article

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Rendering of prostate cancer cells

Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

Darlene Dobkowski, MA
February 13th 2025
Article

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.

Rendering of a bladder and prostate, surrounded by images of cancerous cells

Talazoparib-Enzalutamide Combo Increases OS in mCRPC

Jordyn Sava
February 13th 2025
Article

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.